Down-regulation of miR-301a suppresses pro-inflammatory cytokines in Toll-like receptor-triggered macrophages

Immunology

Volumn 140, Issue 3, 2013, Pages 314-322

  Huang, Lisong ^a   Liu, Yin ^a,b   Wang, Liqiu ^a   Chen, Ruifeng ^a   Ge, Wei ^b   Lin, Zhusen ^a   Zhang, Yun ^a   Liu, Shuyuan ^a   Shan, Yi ^a   Lin, Qingxian ^a   Jiang, Minghong ^b  

^a NAVY GENERAL HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Histone deacetylase inhibitor; Inflammatory response; Macrophage; MiR 301a; Nuclear factor B repressing factor; Toll like receptor

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MICRORNA; MICRORNA 301A; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; GENE EXPRESSION REGULATION; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA ANALYSIS;

HISTONE DEACETYLASE INHIBITOR; INFLAMMATORY RESPONSE; MACROPHAGE; MIR-301A; NUCLEAR FACTOR-ΚB-REPRESSING FACTOR; TOLL-LIKE RECEPTOR;

ANIMALS; CELL LINE; CYCLOOXYGENASE 2; CYTOKINES; GROUP III HISTONE DEACETYLASES; HYDROXAMIC ACIDS; INFLAMMATION MEDIATORS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICRORNAS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PANCREATIC NEOPLASMS; REPRESSOR PROTEINS; TOLL-LIKE RECEPTORS;

EID: 84884962976     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12139     Document Type: Article

References (35)

1. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-76.
2. Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009; 27:693-733.
3. Hoffmann A, Baltimore D. Circuitry of nuclear factor κB signaling. Immunol Rev 2006; 210:171-86.
4. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol 2002; 2:725-34.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97.
6. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011; 11:163-75.
7. Boldin MP, Baltimore D. MicroRNAs, new effectors and regulators of NF-κB. Immunol Rev 2012; 246:205-20.
8. Wendlandt EB, Graff JW, Gioannini TL, McCaffrey AP, Wilson ME. The role of microRNAs miR-200b and miR-200c in TLR4 signaling and NF-κB activation. Innate Immun 2012; 18:846-55.
9. Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-κB signaling. J Mol Cell Biol 2011; 3:159-66.
10. Nourbakhsh M, Hauser H. Constitutive silencing of IFN-β promoter is mediated by NRF (NF-κB-repressing factor), a nuclear inhibitor of NF-κB. EMBO J 1999; 18:6415-25.
11. Nourbakhsh M, Kalble S, Dorrie A, Hauser H, Resch K, Kracht M. The NF-κb repressing factor is involved in basal repression and interleukin (IL)-1-induced activation of IL-8 transcription by binding to a conserved NF-κb-flanking sequence element. J Biol Chem 2001; 276:4501-8.
12. Feng X, Guo Z, Nourbakhsh M, Hauser H, Ganster R, Shao L, Geller DA. Identification of a negative response element in the human inducible nitric-oxide synthase (hiNOS) promoter: the role of NF-κB-repressing factor (NRF) in basal repression of the hiNOS gene. Proc Natl Acad Sci USA 2002; 99:14212-7.
13. Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R. miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J 2011; 30:57-67.
14. Lee EJ, Gusev Y, Jiang J et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120:1046-54.
15. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14:419-27.
16. Liu X, Zhan Z, Li D, Xu L, Ma F, Zhang P, Yao H, Cao X. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 2011; 12:416-24.
17. Jiang M, Xiang Y, Wang D, Gao J, Liu D, Liu Y, Liu S, Zheng D. Dysregulated expression of miR-146a contributes to age-related dysfunction of macrophages. Aging Cell 2012; 11:29-40.
18. T) Method. Methods 2001; 25:402-8.
19. Cao W, Bao C, Padalko E, Lowenstein CJ. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med 2008; 205:1491-503.
20. Shi W, Gerster K, Alajez NM et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 2011; 71:2926-37.
21. Miko E, Czimmerer Z, Csanky E, Boros G, Buslig J, Dezso B, Clynes M, Barron N. Differentially expressed microRNAs in small cell lung cancer. Exp Lung Res 2009; 35:646-64.
22. Beier UH, Akimova T, Liu Y, Wang L, Hancock WW. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Curr Opin Immunol 2011; 23:670-8.
23. Ge Z, Da Y, Xue Z et al. Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Exp Neurol 2013; 241:56-66.
24. Wu C, Li A, Leng Y, Li Y, Kang J. Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets. DNA Cell Biol 2012; 31:592-9.
25. Roger T, Lugrin J, Le Roy D et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117:1205-17.
26. Hancock WW, Akimova T, Beier UH, Liu Y, Wang L. HDAC inhibitor therapy in autoimmunity and transplantation. Ann Rheum Dis 2012; 71(Suppl 2):i46-54.
27. Hancock WW. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation. Handb Exp Pharmacol 2011; 206:103-23.
28. Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009; 9:309-19.
29. Aung HT, Schroder K, Himes SR et al. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J 2006; 20:1315-27.
30. Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ, Dalpke AH. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007; 122:596-606.
31. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D, Huang Q. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109:1123-30.
32. Elsharkawy AM, Oakley F, Lin F, Packham G, Mann DA, Mann J. The NF-κB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes. J Hepatol 2010; 53:519-27.
33. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001; 293:1653-7.
34. Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001; 21:7065-77.
35. Choi YS, Jeong S. PI3-kinase and PDK-1 regulate HDAC1-mediated transcriptional repression of transcription factor NF-κB. Mol Cells 2005; 20:241-6.